The Dengue Vaccine: Who Should Get It and Why

Two dengue vaccines are currently licensed worldwide, and who should receive one depends on the vaccine, the person’s age, and whether they have had dengue before. The World Health Organization recommends Qdenga (TAK-003), the newer of the two, for children aged 6 to 16 in areas with heavy dengue transmission, given as two doses three months apart. The older vaccine, Dengvaxia (CYD-TDV), is approved in some countries but restricted to people with a confirmed previous dengue infection because of safety concerns in those who have never been exposed. That restriction traces back to a biological quirk of dengue that makes the virus unusually difficult to vaccinate against.

Why Dengue Is Hard to Vaccinate Against

Dengue comes in four distinct serotypes. Catching one gives you lasting immunity to that serotype, but your antibodies against it can actually make a future infection with a different serotype worse. This phenomenon, called antibody-dependent enhancement, occurs when leftover antibodies from a previous infection bind to the new virus without neutralizing it. Instead, the antibody-virus complex gets pulled into immune cells more efficiently, which can lead to higher levels of virus in the blood and more severe disease.

A long-running pediatric study in Nicaragua demonstrated this in humans: the risk of severe dengue was highest within a narrow range of pre-existing antibody levels, while high antibody levels were protective against all symptomatic dengue.

¹

This creates a paradox for vaccine developers. A vaccine that generates only a weak or incomplete immune response could leave someone in exactly the vulnerable zone where enhancement kicks in, mimicking a first natural infection and setting the stage for severe disease when the real virus shows up. Any successful dengue vaccine has to thread the needle: produce strong, balanced immunity to all four serotypes without leaving anyone in that dangerous middle ground.

²

Dengvaxia and the Serostatus Problem

Dengvaxia, made by Sanofi Pasteur, became the world’s first licensed dengue vaccine in 2015. It is a chimeric vaccine built on a yellow fever virus backbone with dengue surface proteins swapped in for all four serotypes.

³

Early trial results were encouraging enough for several countries to start mass vaccination campaigns. But follow-up data revealed a serious problem. Among children who had never been infected with dengue before vaccination (called “seronegative”), the vaccine appeared to act like a silent first infection. When these children later encountered wild dengue, they were at elevated risk of severe disease and hospitalization. In the 9-to-11-year-old age group, seronegative vaccinated children were hospitalized for dengue roughly three times more often than would be expected from a natural secondary infection in the general population.

⁴

The fallout was enormous. The Philippines, which had vaccinated over 800,000 schoolchildren, suspended the program. Parents panicked, lawsuits followed, and trust in vaccines more broadly collapsed. Studies of the aftermath found that the Dengvaxia controversy directly fueled measles vaccine hesitancy in parts of the Philippines, contributing to a measles epidemic.

⁵

Dengvaxia is still licensed in several countries but now carries a strict requirement: you must have a confirmed previous dengue infection before receiving it. In the United States, the FDA approved it only for children aged 9 to 16 living in endemic areas who have laboratory-confirmed prior dengue. In practice, this means Dengvaxia’s usefulness is limited by the need for pre-vaccination testing.

The Challenge of Testing Before Vaccination

Confirming whether someone has had dengue before is harder than it sounds. The standard approach uses blood tests that detect anti-dengue antibodies, but these tests face two problems. First, antibodies from other closely related viruses, particularly Zika, can cause false positives. Second, rapid diagnostic tests designed for acute dengue diagnosis often perform poorly when repurposed for detecting old infections, where antibody levels are lower.

A field evaluation in Timor-Leste tested two commercially available rapid tests for this purpose. Both were perfectly specific, meaning they did not produce false positives. But their sensitivity was dismal: one detected only about a fifth of truly seropositive individuals, and the other caught fewer than 5%.

⁶

Sensitivity improved under laboratory conditions rather than field settings, but a gap remains. Newer rapid tests specifically designed for pre-vaccination screening are in development, including the OnSite Dengue IgG test, which has been evaluated retrospectively against phase 3 trial data.

⁷

Until a convenient, accurate field test is widely available, any vaccination strategy that requires knowing serostatus will be logistically challenging in exactly the low-resource settings where dengue hits hardest.

Qdenga and What the Trial Data Show

Qdenga, developed by Takeda, is a live-attenuated vaccine built on a dengue serotype 2 backbone.

⁸

Its phase 3 trial, called TIDES, enrolled over 20,000 children and adolescents across eight countries. The results through about four and a half years of follow-up showed cumulative vaccine efficacy of roughly 61% against lab-confirmed dengue and about 84% against dengue severe enough to require hospitalization.

⁹

The protection was not evenly distributed across serotypes, however. Against dengue serotype 2, efficacy was strong regardless of whether participants had prior dengue exposure, reaching about 80% in seropositive and 88% in seronegative individuals. Serotype 1 protection was moderate. Serotype 3 was the weak spot: in people who had never had dengue, the vaccine showed no meaningful efficacy against DENV-3 at all. And for serotype 4, case numbers were too low to draw conclusions.

⁹

Longer follow-up extending to roughly seven years has indicated that some degree of protection is maintained across all four serotypes over that period.

¹⁰

Crucially, Qdenga has not shown the same safety signal that doomed Dengvaxia’s broad rollout. There has been no clear increase in severe dengue among seronegative vaccinees, which is why the WHO has recommended it without requiring a pre-vaccination blood test. That said, the WHO’s advisory group was deliberate about where to deploy it: settings with high dengue burden and high transmission intensity, to maximize public health impact and minimize any theoretical risk in seronegative individuals.

¹¹

Who Should Get Vaccinated Now

The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommends Qdenga for children aged 6 to 16, ideally administered one to two years before the age at which dengue hospitalizations peak in a given community. The two-dose schedule, with a three-month gap between shots, is straightforward compared to Dengvaxia’s three doses over a year.

¹¹

In the United States, the situation is more limited. Dengvaxia is the only dengue vaccine with FDA approval, and it is restricted to children 9 to 16 in endemic areas like Puerto Rico, the US Virgin Islands, and American Samoa, with proof of previous dengue infection required. Between 2010 and 2020, dengue outbreaks in these territories produced over 30,000 reported cases, about half of them in children, along with 68 deaths.

¹²

Qdenga is authorized in the European Union, the UK, Brazil, Indonesia, Thailand, Argentina, and several other countries. The European Medicines Agency has approved it for use starting at age four, including for travelers heading to endemic regions.

¹³

What About Travelers

If you live in a non-endemic country and plan to visit a region with active dengue, the question of whether to get vaccinated is less clear-cut than it is for residents of endemic areas. Most travelers face relatively short exposure periods, and the vaccine requires two doses three months apart, so the timeline needs planning. Several countries now authorize Qdenga for travelers, but national advisory committees differ on how strongly they recommend it. The Canadian Committee to Advise on Tropical Medicine and Travel, for example, has published guidance acknowledging the authorization of Qdenga for travelers while noting that data on the vaccine’s performance in this specific population remain limited.

The practical consideration: if you are a frequent traveler to dengue-endemic areas, or you plan an extended stay, vaccination may make more sense than for someone taking a single short holiday. Prior dengue exposure matters here too. If you have had dengue before, vaccination is likely to reinforce your existing immunity. If you have never been exposed, the vaccine still appears safe based on available Qdenga data, but the evidence base is thinner for this group, and serotype-specific gaps in protection remain.

Vaccines in the Pipeline

Researchers at the U.S. National Institutes of Health have developed a single-dose live-attenuated vaccine candidate called TV003 (and a variant, TV005). Unlike the two currently licensed vaccines, TV003 may require only one dose. In trials with adults who had no previous flavivirus exposure, a single dose triggered an antibody response to all four dengue serotypes in roughly 74 to 92% of recipients, depending on the formulation.

¹⁴

A human challenge study provided striking results: all 21 vaccinated individuals who were deliberately exposed to dengue serotype 2 six months later were completely protected. None developed detectable virus in their blood, none developed rash, and none showed drops in white blood cell counts. In the placebo group, 100% developed viremia, 80% got a rash, and 20% developed neutropenia.

¹⁵

Phase 2 trials in Bangladesh tested TV005 across multiple age groups, including young children. In adults and older children, the immune response was robust. But in the youngest group, children aged 1 to 4, antibody levels to serotypes 1, 3, and 4 waned by three years, with only about a fifth to a quarter remaining seropositive for those serotypes.

¹⁶

Whether this waning translates to reduced real-world protection or increased risk remains an open question. Large-scale efficacy trials are the next step, and the timeline for licensure will depend on those results.

Vaccination Plus Mosquito Control

Dengue vaccination does not exist in a vacuum. In most endemic countries, vector control remains the primary line of defense. One increasingly prominent approach involves releasing mosquitoes carrying Wolbachia, a bacterium that reduces the mosquito’s ability to transmit dengue. Mathematical modeling has explored what happens when you combine Wolbachia with vaccination. A modeling study estimated that vaccination alone could reduce dengue cases by about 19%, Wolbachia alone by about 92%, and the two together by about 99%.

¹⁷

A more recent modeling study focused on Brazil found smaller but still meaningful effects: a Wolbachia campaign targeting 300 municipalities would avert roughly 16% of cumulative cases, vaccination about 9%, and both together about 24%.

¹⁸

The numbers vary by model assumptions, but the consistent finding is that neither tool alone is likely to eliminate dengue. In Thailand, economic modeling found that once Wolbachia has suppressed transmission substantially, adding vaccination provides only modest additional reductions, because there is simply less virus circulating for the vaccine to protect against.

¹⁹

The practical takeaway: vaccination is one layer of protection, and it works best as part of a broader strategy rather than a standalone solution.

Is Dengue Vaccination Cost-Effective

Cost-effectiveness depends heavily on local transmission intensity and the price of the vaccine. In Thailand, modeling of TAK-003 (Qdenga) at an assumed price of $30 per dose found that routine vaccination of six-year-olds with a ten-year catch-up campaign was not just cost-effective but dominant, meaning it both saved money and improved health outcomes compared to no vaccination.

²⁰

In the Philippines, earlier modeling of Dengvaxia found it cost-effective from a societal perspective when per-person vaccination costs stayed below roughly $75 to $78.

²¹

Puerto Rico, with its moderate transmission intensity and higher healthcare costs, presents a different picture. A modeling study there found much higher costs per quality-adjusted life year gained, with the numbers varying substantially depending on transmission levels and the cost of pre-vaccination screening.

²²

The common thread: in high-transmission tropical settings, dengue vaccination tends to pay for itself. In moderate-transmission settings, the economics get murkier and depend on vaccine pricing, screening costs, and how much you value preventing severe disease in children.

The Lingering Shadow of Vaccine Hesitancy

Even in countries where dengue vaccination makes strong epidemiological sense, willingness to get vaccinated is not guaranteed. The Dengvaxia debacle left deep scars in the Philippines, where routine childhood immunization rates dropped sharply across the board. Research involving over 2,800 Filipino respondents found that government trust, accessibility of vaccines, and seeing others get vaccinated all played significant roles in shaping willingness to accept a dengue vaccine.

²³

The lesson extends beyond the Philippines. Any new dengue vaccination program needs transparent communication about what the vaccine can and cannot do, honest acknowledgment of past mistakes, and accessible delivery systems. Qdenga’s profile is genuinely different from Dengvaxia’s, but telling parents “this one is different” after a previous vaccine harmed children is a harder sell than any efficacy data can solve on its own.

Climate Change and the Expanding Map of Dengue

The question of who should get a dengue vaccine is becoming relevant to a much larger slice of the world’s population. Over the past four decades, the climate zones suitable for dengue-transmitting mosquitoes have expanded considerably. The largest increases in suitability have been in equatorial sub-Saharan Africa, Southeast Asia, and northern South America, but significant expansions have also reached into more temperate zones in North America, East Asia, and the Mediterranean.

²⁴

Projections indicate that much of the southeastern United States could become suitable for dengue transmission by 2050, along with higher-altitude areas in Mexico, northern Argentina, and inland Australia. Coastal cities in eastern China and Japan are also likely to become suitable.

²⁵

Europe is expected to see some of the largest increases in population at risk, with longer transmission seasons driven primarily by the spread of the Aedes aegypti mosquito.

²⁶

These shifts mean that dengue vaccination policy, currently relevant mostly in tropical endemic countries, will increasingly need to be considered by health authorities in places that historically viewed dengue as a traveler’s disease. Southern Europe has already experienced locally acquired dengue cases, and sustained transmission in the southern United States is no longer far-fetched.

Cross-Reactive Immunity From Other Flaviviruses

Dengue does not circulate in isolation. In many parts of the world, people are exposed to Zika virus, yellow fever (including through vaccination), Japanese encephalitis, or other flaviviruses. These viruses are closely enough related that infection with one can shape the immune response to another. Research has shown that the antibody response to any one flavivirus is influenced by a person’s history of prior infections with other members of the same virus family.

²⁷

This has practical implications for dengue vaccination. Someone who has had Zika might test falsely positive on a dengue serostatus screening test, potentially qualifying them for Dengvaxia when they should not. Conversely, pre-existing flavivirus immunity could alter how effectively a dengue vaccine works, though whether that interaction helps or hinders protection remains an active area of research. As both Zika and dengue continue to co-circulate in tropical regions, untangling these cross-reactive immune responses will be important for optimizing vaccination strategies and avoiding the kind of serostatus misclassification that made Dengvaxia’s rollout so fraught.